Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Oncology
Supply Chain
Awards
CRO Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Oncology
Supply Chain
Awards
CRO Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
macular degeneration
Manufacturing
Manufacturing issues cause FDA to delay decisions on Eylea HD
The FDA has extended its target action dates for two applications to expand the use of Eylea’s high-dose formulation.
Kevin Dunleavy
Aug 20, 2025 2:32pm
Apellis expects sales of Syfovre to decline in Q1
Feb 28, 2025 3:05pm
FDA gives thumbs-up to Roche's Susvimo as treatment for DME
Feb 4, 2025 3:15pm
Asian patients with PCV show improvement with Roche's Vabysmo
Nov 22, 2024 7:00am
Eylea HD sales jump in Q3 but Regeneron still cedes market share
Oct 31, 2024 11:37am
Regeneron touts Eylea HD launch, warns of potential approval delay
Aug 1, 2024 11:15am
